Research
Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer
NEJM ·
The Brief
- A New England Journal of Medicine correspondence titled 'Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer' was published.
- It appears in Volume 395, Issue 20, pages 2073-2075, with an issue date of November 19, 2026.
- The provided source contains only the title and citation, so no trial results or methods are available here.
Why it matters
The letter concerns combined enfortumab vedotin and pembrolizumab treatment for bladder cancer in patients who are eligible for cisplatin, a setting relevant to clinicians treating this disease. The source provided does not include its findings, so the practical implications cannot be assessed from it.
Who’s affected
- oncologists and urologists treating bladder cancer
- bladder cancer patients and their families
- #bladder cancer
- #oncology
- #immunotherapy
- #enfortumab vedotin
- #pembrolizumab
New England Journal of Medicine, Volume 395, Issue 20 , Page 2073-2075, November 19, 2026.